[225Ac]Ac-SibuDAB

The main aim of this study was to evaluate the current state of bibliometric and altmetric research output of [²²⁵Ac]Ac-Prostate specific membrane antigen (PSMA) and its implications for prostate cancer (PC). Both PubMed and Scopus digital libraries were systematically explored to retrieve relevant data on the topic of interest. The study of various bibliometric and altmetric indices was facilitated through the use of Microsoft Excel, Stata (Version 17.0), and VOSviewer (Version 1.6) Softwares. The parameters included in this study comprised the examination of published articles, annual trends, countries, institutions, authors, journals, and co-occurring keywords. From 2014 to 2024, our study examined a total of 100 publications within the given domain. The studies that received the highest citations primarily centered on the crucial topic of metastatic castration-resistant prostate cancer, with a particular emphasis on evaluating the safety and effectiveness of [²²⁵Ac]Ac-PSMA therapy. Moreover, much scholarly inquiry has been devoted to examining the [²²⁵Ac]Ac-PSMA adverse effects. Three high prolific countries (namely, Germany, United States, and South Africa) dominated the research render in terms of publications and citations. Finally, A strong correlation was observed between altmetric score and citation number (P < 0.001). The observed surge in scholarly research output and altmetric indicators associated with [²²⁵Ac]Ac-PSMA signifies a shift in emphasis towards embracing alpha targeted therapy in PC.

Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa). Actinium-225 (²²⁵Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in some cases sustained antitumor responses. The development of radiolabeling techniques involving EDTA, DOTA, DOTPA, and Macropa chelators has laid the groundwork for advancements in this field. At the forefront of clinical trials with ²²⁵Ac in PCa are PSMA-targeted TAT agents, notably [²²⁵Ac]Ac-PSMA-617, [²²⁵Ac]Ac-PSMA-I&T and [²²⁵Ac]Ac-J591. Ongoing investigations spotlight [²²⁵Ac]Ac-hu11B6, [²²⁵Ac]Ac-YS5, and [²²⁵Ac]Ac-SibuDAB, targeting hK2, CD46, and PSMA, respectively. Despite these efforts, hurdles in ²²⁵Ac production, daughter redistribution, and a lack of suitable imaging techniques hinder the development of TAT. To address these challenges and additional advantages, researchers are exploring alpha-emitting isotopes including ²²⁷Th, ²²³Ra, ²¹¹At, ²¹³Bi, ²¹²Pb or ¹⁴⁹Tb, providing viable alternatives for TAT.